依洛尤单抗治疗高胆固醇血症的长期降脂疗效、持续性与安全性:OSLER-1开放标签扩展研究至4年结果
OSLER-1为在18国192中心开展的随机开放标签扩展试验,1324例完成二期父研究的患者入选,1255例至少接受1次依洛尤单抗420 mg。第52周时依洛尤单抗联合标准治疗较单用标准治疗显著降低低密度脂蛋白胆固醇(LDL-C)61%对2%(P<.001),随访约2、3、4年时中位LDL-C降幅分别为59%、59%、57%,未检出中和抗体,79%患者持续治疗,平均暴露44个月。
要点
- 依洛尤单抗联合标准治疗第52周LDL-C降低61%,单用标准治疗降低2%(P<.001)。
- 约2、3、4年随访中位LDL-C降幅分别为59%、59%、57%,疗效持续。
- 未检出中和抗体,79%患者持续用药,平均暴露44个月。
核心结论
- 在迄今对PCSK9抑制剂最长的临床试验暴露中,依洛尤单抗产生持续的低密度脂蛋白胆固醇降低,且不良事件年发生率未随开放标签观察中的累积暴露而增加。
研究设计与样本
- OSLER-1为正在进行的随机开放标签扩展试验,在18个国家192个中心开展,2011年10月至2016年8月进行,数据截止2016年8月26日。
- 1666例随机进入5项为期12周的双盲二期父研究的患者中1324例完成父研究并选择参加OSLER-1,其中1255例接受1次或以上依洛尤单抗剂量。
- 截至2016年8月,1324例中812例(61%)随访满208周。
- 第1年患者随机接受依洛尤单抗420 mg联合标准治疗或单用标准治疗,第1年后所有继续研究者均接受依洛尤单抗420 mg联合标准治疗。
- 父研究基线时平均(SD)年龄57.1(11.6)岁,女性占52.9%,中位低密度脂蛋白胆固醇133 mg/dL。
主要发现
- 第52周时依洛尤单抗联合标准治疗使低密度脂蛋白胆固醇降低61%(95%CI -63%至-60%),单用标准治疗降低2%(95%CI -5%至-0.2%),P<.001。
- 研究随访约2、3、4年时,中位低密度脂蛋白胆固醇较父研究基线分别降低59%(95%CI -60%至-57%)、59%(95%CI -61%至-58%)、57%(95%CI -59%至-55%)。
- 他汀治疗自基线未变的患者第208周中位低密度脂蛋白胆固醇降低58%。
- 未检出针对依洛尤单抗的中和抗体;新发糖尿病年化发生率单用标准治疗组为4%,依洛尤单抗联合标准治疗组按依洛尤单抗暴露时长校正后为2.8%。
- 神经认知事件发生率单用标准治疗组为0%,依洛尤单抗联合标准治疗组为0.4%;79%患者持续依洛尤单抗治疗,平均暴露时长44个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Open-Label Study of Long-term Evaluation Against LDL-C (OSLER-1) evaluated the durability of long-term efficacy and safety during long-term therapy with evolocumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9). OBJECTIVE: To determine whether LDL-C level reductions with evolocumab persist across different populations. Secondary objectives included assessment of adverse events, antidrug antibodies, and factors contributing to treatment discontinuation. DESIGN, SETTING, AND PARTICIPANTS: This ongoing, randomized open-label extension trial (OSLER-1) was conducted at 192 sites in 18 countries. A total of 1324 of 1666 patients randomized into 1 of 5 12-week double-blind phase 2 parent studies completed a parent study and chose to participate in OSLER-1; 1255 received 1 or more evolocumab doses. As of August 2016, 812 of 1324 (61%) had 208 weeks of follow-up. This current study was conducted from October 2011 to August 2016, with a data cutoff of August 26, 2016. INTERVENTIONS: During year 1, patients were randomized to evolocumab, 420 mg, plus standard of care (SOC) or SOC alone. After year 1, all patients continuing the study received evolocumab, 420 mg, plus SOC. MAIN OUTCOMES AND MEASURES: Lipids, safety, and tolerability every 12 weeks. A multivariate model identified factors associated with discontinuation of evolocumab. RESULTS: At parent study baseline, the mean (SD) age of the population was 57.1 (11.6) years, with 52.9% being women. The median LDL-C level was 133 mg/dL (to convert to millimoles per liter, multiply by 0.0259). After 52 weeks, evolocumab plus SOC was associated with a significant reduction in LDL-C level by 61% (95% CI, -63% to -60%) vs 2% (95% CI, -5% to -0.2%) with SOC alone (P < .001). At approximately 2, 3, and 4 years of study follow-up, the median LDL-C level was reduced by 59% (95% CI, -60% to -57%), 59% (95% CI, -61% to -58%), and 57% (95% CI, -59% to -55%), respectively, from parent study baseline. For patients receiving statin therapy unchanged from baseline, at week 208, the median LDL-C level reduction was 58%. No neutralizing antibodies to evolocumab were detected. The annualized incidence of new-onset diabetes was 4% in the SOC alone group and, adjusting for duration of evolocumab exposure, 2.8% in the evolocumab plus SOC group. Neurocognitive event rates were 0% (SOC alone) and 0.4% (evolocumab plus SOC). A total of 79% of patients persisted with evolocumab treatment, with a mean exposure duration of 44 months. CONCLUSIONS AND RELEVANCE: In the longest clinical trial exposure to a PCSK9 inhibitor to date, evolocumab produced sustained reductions in LDL-C levels. The annual frequency of adverse events did not occur more frequently with cumulative exposure during open-label observation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01439880.
引用
- Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017. PMID: 28291870. doi:10.1001/jamacardio.2017.0747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。